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ETV6/TEL is the first transcription factor identified that is specifically required for hematopoiesis within the bone marrow. This
gene has been found to have multiple fusion partners of which 16 have been cloned. Fluorescence in situ hybridization (FISH)
analysis in a patient with myelodysplastic syndrome (MDS) revealed a t(1;12)(p36;p13) involving ETV6, with the breakpoint in
this gene between exon 2 and exon 3. We report here the cloning of a novel ETV6 partner located on 1p36.1, involved in the
t(1;12). 3 RACE-PCR from RNA identified a novel sequence fused to exon 2 of ETV6. Database searches localized this
sequence in a bacterial artificial chromosome (BAC) mapped to 1p36 by fingerprint analysis. This result was confirmed by FISH
using this BAC as probe. 5 and 3 RACE experiments with primers from this novel sequence were carried out on RNA from
a healthy donor and identified a novel full-length mRNA, which we named MDS2 (myelodysplastic syndrome 2). RT-PCR
experiments were performed on a panel of human cDNAs to analyze the expression pattern of this gene and they revealed
four splicing variants. RT-PCR analysis showed that ETV6-MDS2, but not the reciprocal MDS2-ETV6 fusion transcript, was
expressed in the bone marrow of the patient. The product of the ETV6-MDS2 fusion transcript predicts a short ETV6 protein
containing the first 54 amino acids of ETV6 plus four novel amino acids, lacking both the PTN and the DNA-binding domains.
Possible mechanisms to account for the development of MDS in this patient are discussed. © 2002 Wiley-Liss, Inc.
INTRODUCTION
ETV6/TEL is the ﬁrst transcription factor identi-
ﬁed that is speciﬁcally required for hematopoiesis
within the bone marrow (Wang et al., 1998). This
gene is rearranged in half of the patients with
12p13 translocations, in both myeloid and lym-
phoid leukemias (Sato et al., 1997; Odero et al.,
2001). ETV6 has been found to have multiple fu-
sion partners; using ﬂuorescence in situ hybridiza-
tion (FISH), more than 40 different chromosome
bands have been reported to be involved in ETV6
translocations (reviewed in Odero et al., 2001), and
16 partner genes have been cloned: ARNT (1q21),
ARG (1q25), MDS1/EVI1 (3q26), CHIC2/BTL
(4q12), ASC2 (5q13), PDGFRB (5q33), STL (6q23),
MNX1 (7q36), PAX5 (9p13), JAK2 (9p24), SYK
(9q22), ABL (9q34), CDX2 (13q12), TRKC (15q25),
CBFA2 (21q22), and MN1 (22q11) (Golub et al.,
1994, 1995; Romana et al., 1994; Buijs et al., 1995;
Papadopoulos et al., 1995; Peeters et al., 1997a,b;
Suto et al., 1997; Cazzaniga et al., 1999, 2001;
Chase et al., 1999; Cools et al., 1999; Eguchi et al.,
1999; Yagasaki et al., 1999; Iijima et al., 2000;
Salomon-Nguyen et al., 2000; Beverloo et al., 2001;
Kuno et al., 2001). The ETV6 gene codes for a
ubiquitously expressed nuclear protein that con-
tains two critical domains, the 5 pointed (PTN)
domain (coded for by exons 3 and 4) and the 3 E26
transformation-speciﬁc (ETS) DNA-binding do-
main (exons 6–8). The translocation breakpoints
are distributed throughout the gene, and ETV6
contributes to the pathogenesis of leukemia by
remarkably diverse molecular mechanisms that are
only partially understood. Molecular characteriza-
tion of chromosomal translocations involving ETV6
showed that many of them result in the expression
of chimeric proteins; the most common involve
fusion between the amino-terminal part of ETV6
and either unrelated transcription factors or protein
tyrosine kinases. However, in a number of cases,
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including a t(6;12)(q23;p13) (Suto et al., 1997), the
recurrent t(5;12)(q31;p13) (Yagasaki et al., 1999),
and some t(4;12)(q11–12;p13) (Cools et al., 2002),
functionally signiﬁcant fusions could not be de-
tected.
We report here the identiﬁcation and character-
ization of a novel gene, MDS2 (myelodysplastic
syndrome 2), involved in a rearrangement with
ETV6 in a t(1;12)(p36;p13), in a patient with my-
elodysplastic syndrome (MDS).
MATERIALS AND METHODS
Case Report
A 66-year-old Caucasian woman was admitted to
our institution because of weakness lasting for a
year. There were no signs or symptoms at admis-
sion, except for the presence of mild gingival
bleeding. The patient reported no fever or infec-
tious episodes during the previous weeks, and
there was no history of hematological malignancy.
Blood count showed Hb 8.8 g/dL, white cell count
3.3  109/L with 3% blast cells, and platelet count
104  109/L. No liver or kidney dysfunction was
detected on serum biochemical determinations.
Prothrombin time and activated partial thrombo-
plastin time were within normal ranges. The bone
marrow aspirate was hypercellular, showing 23%
blast cells and red cell hyperplasia with dysplastic
changes in erythroblasts (intercytoplasmatic bridges,
binucleated cells, and megaloblastosis). Flow cy-
tometry of bone marrow cells showed that the blast
cells were CD34, CD13, CD33, and HLA-DR pos-
itive. The patient was diagnosed with MDS
(RAEBT). She refused any treatment other than
transfusion therapy. Disease evaluation after 6
months showed Hb 8.1 g/dL, white cell count
4.2  109/L with 5% blast cells, and platelet count
45  109/L. Bone marrow aspiration showed 52%
blast cell inﬁltration with the same characteristics
as those observed at diagnosis. Conditions deteri-
orated further, and the patient died 8 months after
diagnosis.
Cytogenetic and FISH analyses of this patient
were described previously (Odero et al., 2001). The
karyotype showed a single clone with two recipro-
cal translocations, a t(1;12)(p36;p13) and a t(9;
11)(q34;q13). The sample was obtained at relapse,
with informed consent. Only ﬁxed cells were avail-
able for cytogenetic and molecular studies.
Fluorescence In Situ Hybridization
Cosmid clones for the ETV6 locus were de-
scribed previously (Odero et al., 2001). BACs and
PACs located on chromosomes 1, 9, and 11 were
identiﬁed by database searches, obtained from li-
braries from the Roswell Park Cancer Institute
(Buffalo, NY), and used to map the breakpoints in
the two translocations present in the patient. Three
BACs and three PACs located in chromosome 1
were selected to map the breakpoint on 1p36.
Eleven BACs located in chromosome 9 and 10 in
chromosome 11 (all from the RPCI-11 library) were
used in FISH experiments to map the breakpoint
in the t(9;11)(q34;q13). The order of the probes in
chromosome 9 is: centromere–696J10–498E2–
282P20–545E17–98H23–247A12–492E3–138E2–
7M2–17L7–253A1–telomere. The order of the BACs
in chromosome 11 is: centromere–77M17–163K24–
877I6–669D23–142N13–699D24–259D17–154D10–
699M19–300I6–telomere.
Nucleid Acid Isolation
Total RNA was extracted from ﬁxed cells using
TriReagent (Molecular Research Center, Cincin-
nati, OH). cDNA was generated with the First-
strand cDNA Synthesis kit (Clontech, Palo Alto,
CA) and was used as template for PCR. Previous
experiments using ﬁxed cells from the THP-1 and
U-937 cell lines were done to conﬁrm the feasibil-
ity of the technique and to adjust the concentration
of DNA needed in the PCR reactions. The quality
of cDNA in the patient sample was conﬁrmed by
ampliﬁcation of the normal ETV6 gene. In subse-
quent experiments, RNA was extracted using the
GenElute Mammalian Total RNA Isolation kit
(Sigma Chemical, St. Louis, MO), and cDNA was
prepared using SuperScript II RNase H Reverse
Transcriptase (Life Technologies, Gaithersburg,
MD).
Rapid Amplification of cDNA Ends (RACE)
Polymerase Chain Reaction (PCR)
For 3 RACE, nested PCR was performed using
the primers TELex2-F1 and TELex2-F2, both in
exon 2 of ETV6 (3 RACE System for Rapid Am-
pliﬁcation of cDNA Ends; Life Technologies). For
5 RACE, nested PCR was performed using the
primers TELex3-R2 and TELex3-R1 (5 RACE
System for Rapid Ampliﬁcation of cDNA Ends;
Life Technologies). Both 3 and 5 RACE in the
normal donor were performed using the Gene-
Racer kit (Invitrogen BV, Groningen, The Neth-
erlands), which selects for RNAs containing the
cap structure. Primers NGex6-F1 and NGex6-R1
were used for initial 3 RACE and 5 RACE am-
pliﬁcations, and primers NGex6-F2 and NGex6-R2
for the respective nested reactions. These primers
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were carefully designed to be compatible with the
primers included in the kit. All primer sequences
are shown in Table 1.
Reverse Transcriptase–PCR
RT-PCR reactions were carried out with Ampli-
Taq Gold DNA Polymerase (Applied Biosystems,
Foster City, CA) after optimizing cycling condi-
tions for each primer pair. To conﬁrm the presence
of the fusion product, nested RT-PCR was per-
formed on patient RNA with the TELex1-F1 and
TELex2-F3 forward primers in ETV6 exon 1 and
exon 2, respectively, and the NG-R1 reverse
primer in the new gene.
Analysis of the expression pattern of MDS2 was
performed by RT-PCR using primers NGex1-F1
and NGex6-R1 on a set of normalized, ﬁrst-strand
cDNA from 16 different human tissues (Multiple
Tissue cDNA Panels I and II; Clontech, Basing-
stoke, UK), following the manufacturer’s protocols.
These primers are located in exon 1 and exon 6 of
MDS2, respectively. All ampliﬁcations were per-
formed for 35 cycles with an annealing temperature
of 60°C.
Semiquantitative RT-PCR
Expression levels of several genes were com-
pared by semiquantitative RT-PCR. For each re-
action, serial dilutions of a control cDNA from
peripheral blood lymphocytes were included to
check that all samples analyzed were within the
linear range of the ampliﬁcation reaction. All reac-
tions were normalized to G3PDH expression levels
in the same samples (also obtained in the linear
phase of ampliﬁcation) after densitometric analysis
of the gels. The primer sequences are shown in
Table 1.
DNA Cloning and Sequencing
Products were cloned either into the pMOS
(Amersham Pharmacia Biotech UK, Buckingham-
shire, UK) or into the pCR 4-TOPO vector (TOPO
TA Cloning Kit for Sequencing; Invitrogen BV)
and were sequenced with ABI-PRISM d-Rhoda-
mine Terminator Cycle Sequencing Kit (Applied
Biosystems) in an ABI 377 DNA Sequencer (Ap-
plied Biosystems).
RESULTS
Cloning of the t(1;12)
The karyotype of this patient was described pre-
viously (Odero et al., 2001). G-banding, FISH, and
spectral karyotyping (SKY) showed a single clone
with two translocations: t(1;12)(p36;p13) and t(9;
11)(q34;q13) (Fig. 1A). FISH analysis with ETV6
probes localized the breakpoint in this gene be-
tween exon 2 and exon 3 (Odero et al., 2001).
To identify the fusion partner of ETV6, 3 and 5
RACE-PCR experiments were performed on re-
TABLE 1. Oligonucleotide Primer Sequences
Primer Gene Oligonucleotide sequences (5 3 3)
TELex2-F1 ETV6 CAGGAACGAATTTCATATACACCT
TELex2-F2 ETV6 CCAGTGCCGAGTTACGCTTCCT
TELex3-R1 ETV6 CTTTGGTCAGCAGCAGGAGAGC
TELex3-R2 ETV6 CTGAATGAGGAGATCGATAGCG
TELex1-F1 ETV6 TCCTGATCTCTCTCGCTG
TELex2-F3 ETV6 TCCAGAGAGCCCAGTGCC
NG-R1 MDS2 GCGACAGCCAGGTCTTAA
NGex1-F1 MDS2 CCGCCTGTATCCGTGCCTGTT
NGex6-F1 MDS2 AGCAGTCCAGCTATGAGGGGAGGT
NGex6-R1 MDS2 TGGAGGCGACAGCCAGGTCTTAA
NGex6-F2 MDS2 GACCCTGGAGAGGCCATTAAGACCT
NGex6-R2 MDS2 GTCTTAATGGCCTCTCCAGGGTCAG
RP-F RPL11 AGGTGCGGGAGTTGGAGTTA
RP-R RPL11 TGTCCTGCGCTTCTTGTCTG
ELA-F TCEB3 TCCGGAGGAGGCAGGAAAAGTT
ELA-R TCEB3 CCCCAACCCCCACTGTCCTTGTA
X69111-F ID3 CCCCGGTATCAGCGCTTCCTCATT
X69111-R ID3 CGCCTTCATGCTGGGGAGTGAGT
E2F2-F E2F2 ACGCCAGGGTCGGGGACAGGAA
E2F2-R E2F2 GCACCCAAGGGCCCATCGAAGTC
G3PDH1-F G3PDH TGAAGGTCGGAGTCAACGGATTTGGT
G3PDH2-R G3PDH CATGTGGGCCATGAGGTCCACCAC
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verse-transcribed RNA obtained from bone marrow
of the patient. Because the FISH results had indi-
cated that the breakpoint was between ETV6 exons
2 and 3, nested primers located in exons 2 and 3 of
ETV6 were used for 3 and 5 RACE-PCR experi-
ments, respectively. All 3 RACE-PCR products
were cloned, and 11 clones were sequenced. Six
clones represented the normal ETV6 allele, three
clones were possible genomic sequences (exon 2
followed by intron 2), and two clones contained 116
bp of novel sequence immediately after ETV6 exon
2. BLAST searches against the HTGS database
localized this sequence to BAC 223J15 from the
RPCI-11 library (accession no. AC068847), which
maps to 1p36.1. This ﬁnding was consistent with
the initial cytogenetic data and revealed that it
could be an exon belonging to a novel gene. 5
RACE-PCR from ETV6 exon 3 failed to ﬁnd any
novel sequences.
FISH Analysis
To conﬁrm the position of the breakpoint, three
BACs and three PACs located on 1p36.1 were se-
lected from RPCI libraries, including clone 223J15.
The exact position of the clones along 1p36.1 was
still tentative at the beginning of the analysis,
given that sequencing of this region by the HGP is
in progress. Our FISH studies were consistent with
the following order: telomere-RP1–150O5-RP11–
519D12-RP11–223J15-RP4–633K13-RP11–509F14-
RP3–462O23–centromere.
FISH analysis on bone marrow cells from the
patient showed that clone 223J15 hybridized to
both the normal chromosome 1 and the der(1),
whereas clone 150O5 hybridized to the normal
chromosome 1 and the der(12). Clone 519D12,
which overlaps with 223J15, was present in the
normal chromosome 1 and in both der(1) and
der(12), indicating the localization of the break-
point in this case (Fig. 1B).
To determine whether the breakpoint is recur-
rent in other cases, we checked samples from 10
patients with hematological malignancies and re-
ciprocal translocations involving 1p36. The clones
used as probes were 150O5 and 223J15, which
ﬂank the clone that splits in the patient with t(1;
12). In all cases, both probes hybridized to the
same chromosome, either chromosome 1 or the
other chromosome involved in the translocation
(data not shown), suggesting that the breakpoints
were not within the region covered by the probes.
Eleven BACs on chromosome 9 and 10 BACs on
chromosome 11 were used in metaphase FISH
experiments, to map the breakpoint in the t(9;
11)(q34;q13). The breakpoint in chromosome 9
was mapped to 9q34.13, between RP11 98H23 and
247A12, centromeric to ABL. Surprisingly, there
were two breakpoints on 11q13.4: 142N13 shows
one signal in the normal chromosome 11, whereas
the other signal splits and hybridizes to both the
der(11) and chromosome 21 (weaker signal);
699D24 shows one signal on normal chromosome
11, and another signal splits on both der(21) and
der(9) (weaker signal), indicating that this is a com-
plex translocation involving not only chromosome
21 but also chromosomes 9 and 11 (data not
shown). Further studies are required to know the
genes involved in this translocation.
Figure 1. G-banding, SKY, and FISH analyses of the patient. A: G-banding and SKY analyses showing the
t(1;12) and t(9;11). B: RP11 519D12 probe (red) from chromosome 1 labels normal chromosome 1, and
both der(1) and der(12).
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Characterizing the New Gene
Our ﬁnding that the 116 bp of novel sequence
were included in the region of overlap between
clone 223J15 and clone 519D12, which splits in the
translocation, prompted us to check whether this
sequence could be part of a gene, given that align-
ments with genomic sequences had shown that the
novel sequence was ﬂanked by consensus GT and
AG splice signals. For this purpose, 5 and 3
RACE reactions were performed on RNA from a
normal donor, using primers located in the new
sequence, and yielded various bands that were
cloned and sequenced (not shown). These se-
quences were assembled and analyzed against the
human genome sequence database using various
resources, and they also matched the same BAC
clone as the original 116-bp sequence. Further-
more, alignment of these sequences with genomic
DNA revealed the presence of novel exons, all of
them ﬂanked by consensus splicing sequences.
From these experiments, we were able to iden-
tify three exons upstream of the original sequence,
plus one downstream exon that contained a poly-A
tail. The longest 5 fragment identiﬁed an up-
stream exon ﬂanked by a consensus GT splicing
site at its 3 end but lacking a consensus AG splic-
ing site at its 5 end. Instead, a canonical TATA
box was located 25 bp upstream of the ﬁrst nucle-
otide of this exon, indicating that this is probably
the ﬁrst exon of a novel gene, and further pinpoint-
ing the location of the putative promoter. The
presence of both a ﬁrst exon and a poly-adenine tail
conﬁrmed that the various 5 RACE and 3 RACE
fragments encompassed a novel, full-length mRNA
that we named MDS2 (myelodysplastic syndrome 2).
MDS2 Gene
We analyzed the expression of this novel mRNA
on a panel of human cDNAs using an RT-PCR
designed to amplify the 5 half of the novel gene
(primers NGex1-F1 and NGex6-R1). This experi-
ment revealed a major band of 281 bp, which was
stronger in peripheral blood leukocytes (PBLs),
spleen, thymus, kidney, pancreas, and lung. This
band was also present in other tissues, although at
lower abundance, and was completely absent in
brain and testis (Fig. 2A). Additional bands of
weaker intensity were obvious in most tissues; we
did a Southern blot of this gel and hybridized the
ﬁlter with a probe consisting of an internal frag-
ment of the major 281-bp band, from which the
primer sequences had been removed. All the minor
Figure 2. Analysis of the expression of MDS2 in a panel of human cDNAs. A: RT-PCR amplification of
MDS2, using primers in exon 1 and exon 6, reveals a main band present in most tissues. Minor bands were
cloned and sequenced, and shown to represent alternatively spliced forms (arrowheads and roman
numerals). B: Schematic representation of the four splicing variants detected in A.
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bands hybridized with the probe, indicating that
they were speciﬁc products, probably representing
alternatively spliced forms of the gene. We cloned
and sequenced all the minor bands from these
reactions and conﬁrmed that they corresponded to
alternatively spliced products. This analysis also
revealed two new exons that had not been found in
the previous RACE experiments (exons 3 and 5)
and provided a complete picture of the splicing
patterns present in different human tissues.
Putting together all the data from RACE and
RT-PCR experiments, we identiﬁed a novel gene
containing seven exons (accession no. AJ310434).
The MDS2 gene spans approximately 13 kb and is
ﬂanked by E2F2 and ID3 at its 5 end (telomeric)
and by RPL11 and TCEB3 at its 3 end (centromeric)
and gives rise to four alternatively spliced products
(Fig. 2B). The major mRNA (referred to as form I)
is made up of exons 1, 4, 6, and 7 and is expressed
mainly in thymus, spleen, PBLs, pancreas, lung,
kidney, and at lower levels in ovary, prostate, liver,
small intestine, placenta, colon, and skeletal mus-
cle. It is not expressed in brain and testis. The
second most frequently found mRNA (form II) is
the result of splicing together of exons 1, 3, 4, 6,
and 7. This form was found predominantly in
spleen, thymus, and kidney, and at much lower
levels in lung, pancreas, placenta, and PBLs. Form
III contains exons 1, 4, 5, 6, and 7 and is present in
pancreas, skeletal muscle, and PBLs. Form IV is
the rarest and largest of all, containing exons 1, 2, 3,
4, 6, and 7; it is present only in brain.
Computer analysis revealed that forms I, II, and
IV all have the potential to encode the same pep-
tide of 82 amino acids, starting at an ATG located
in exon 6, whereas form III could be translated into
a longer protein because of the addition of exon 5.
This protein is predicted to have a size of 140
amino acids, including the 82 carboxy-terminal
amino acids that are identical to the peptide pre-
dicted by the other splicing variants.
RT-PCR Experiments in the Sample From the
Patient
Nested RT-PCR reactions were performed on
patient RNA with forward primers TELex1-F1
and TELex2-F3 in ETV6 exon 1 and exon 2, re-
spectively, and reverse primer NG-R1 in exon 6 of
MDS2. The PCR products were cloned and se-
quenced, conﬁrming the fusion between exon 2 of
ETV6 and exon 6 of MDS2 that had been found in
the original RACE experiment. The predicted
ETV6-MDS2 fusion product contains 58 amino ac-
ids, starting at the ﬁrst ATG of ETV6 and ending in
a TGA stop codon only four amino acids after ETV6
exon 2 (Fig. 3). Because the sequences from both
genes are not in frame, the fusion transcript en-
codes the ﬁrst 54 amino acids of ETV6, followed by
four additional novel amino acids encoded by
MDS2 sequences. This predicts a truncated ETV6
protein that lacks both the PTN domain and the
DNA-binding domain encoded in the C-terminal
region of ETV6. No RT-PCR ampliﬁcation prod-
ucts could be obtained using forward primers in
MDS2 exon 6 and reverse primers in ETV6 exon 4,
indicating that the reciprocal MDS2-ETV6 fusion is
probably not expressed in the bone marrow in this
patient (data not shown). This would be in agree-
Figure 3. Detection of the ETV6-MDS2 fusion in the patient. A: RT-PCR showing amplification of the
fusion product in the bone marrow from the patient (lane 3) but not in normal bone marrow (lane 2). M 
100-bp ladder. Lane 1  water control. B: Schematic representation of the breakpoint (arrow) and the
result of the fusion transcript. ETV6 exon 2 sequence (bold) is followed by MDS2 exon 6 (italics).
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ment with the initial 5 RACE experiments from
ETV6 exon 3, which failed to identify chimeric
transcripts.
Changes in the Expression of Neighboring Genes
Because the t(1;12) did not result in a fusion
protein to which an oncogenic function could be
attributed, we checked whether the translocation
could affect the expression of known genes ﬂank-
ing MDS2. We identiﬁed candidate genes in the
genomic sequence surrounding MDS2 and de-
signed semiquantitative RT-PCR experiments to
compare the expression of E2F2, ID3, RPL11, and
TCEB3 between the patient and three unrelated
nontumor samples (all samples were from bone
marrow). As shown in Figure 4, the expression of
RPL11 was 26 times higher in the patient than that
in controls.
DISCUSSION
We report here the characterization of a novel
gene,MDS2, fused to ETV6 in a t(1;12)(p36;p13) in
a patient with MDS. The previous mapping of the
breakpoint on 12p13 between exon 2 and exon 3 of
ETV6 using FISH (Odero et al., 2001) allowed for
the molecular study using ﬁxed cells, the only ma-
terial that was available. The MDS2 gene spans
around 13 kb and seven exons accounting for the
cDNA sequence were identiﬁed. RT-PCR exper-
iments on a panel of human cDNAs, to analyze the
expression pattern of this gene, showed that it is
widely expressed in tissues and further revealed
four splicing variants. MDS2 is located in a GC-rich
genomic region that encompasses the terminal 48
Mb of the short arm of chromosome 1. This region
is rich in repeated elements, and it is particularly
interesting that MDS2 noncoding exons 1, 2, 3, and
4 are included in consensus SINE or LINE se-
quences (detected by RepeatMasker), whereas
part of exon 7 is embedded in an LTR repeat. The
longest open reading frame predicted from MDS2
has 140 amino acids and shows no signiﬁcant ho-
mology to any known protein.
In the ETV6-MDS2 fusion, exon 2 of ETV6 is
followed by exon 6 of MDS2. This predicts a trun-
cated ETV6 protein that is unlikely to play an
important role in the oncogenic process because it
lacks both the PTN domain and the ETS DNA-
binding domain.
ETV6 is an active repressor of transcription and
the ETV6-CBFA2 fusion protein has been sug-
gested to exert its oncogenic properties through a
dominant-negative effect on normal CBFA2 func-
tion (Lopez et al., 1999; Fenrick et al., 2000). It
could be speculated that the ETV6-MDS2 fusion
protein interacts with either the ETV6 gene or the
MDS2 gene. However, the repressor activities seem
to be dependent on the integrity of the ETV6 PNT
oligomerization domain and on its self-association
properties. Therefore, the fact that the predicted
fusion protein lacks both main functional domains
of ETV6 suggests a loss of function rather than a
dominant effect.
The role of the fusion protein in the leukemic
cells still has to be fully investigated. In the t(1;12)
described here, both ETV6 and MDS2 genes are
expressed from the nontranslocated copies of the
gene. Because the reciprocal MDS2-ETV6 fusion is
not expressed, it can be concluded that bone mar-
row cells from this patient have only one function-
ing allele of MDS2. Haploinsufﬁciency could ac-
count for the leukemogenic process if MDS2 is a
dosage-sensitive gene, but this is unknown at
present. Alternatively, the combined loss of one
allele of ETV6 and one allele of MDS2 could be
responsible for the MDS in this patient. MDS2
could also code for a nontranslated transcript that
inhibits the expression of an overlapping gene
Figure 4. Analysis of the expression levels of genes surrounding
MDS2 in the patient and in three unrelated normal bone marrow
samples. A: Semiquantitative RT-PCR for G3PDH, E2F2, ID3, RPL11, and
TCEB3. For each PCR, one normal bone marrow (N) and the patient’s
bone marrow (P) are shown. Lanes 1 to 4 represent serial dilutions of
a standard cDNA, showing that all PCR reactions are in the linear phase
of amplification. B: Graphical representation, including the results ob-
tained for three different normal samples, after densitometric analysis of
the gels.
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through an antisense effect. The short ORF and
the lack of strong homology to known protein do-
mains seem to support this hypothesis. In this re-
gard, computer analysis of the region predicts sev-
eral genes, transcribed from the complementary
strand, which overlap the 3 end of MDS2. We are
currently analyzing whether any of these predic-
tions represents an expressed sequence.
ETV6 has been shown to be fused to many part-
ner genes, most of them encoding either protein
tyrosine kinases or other unrelated transcription
factors. However, in a number of cases, including a
t(6;12)(q23;p13) (Suto et al., 1997), the recurrent
t(5;12)(q31;p13) (Yagasaki et al., 1999), and some
t(4;12)(q11–12;p13) (Cools et al., 2002), function-
ally signiﬁcant fusions could not be identiﬁed. It
has been reported that dysregulation of the expres-
sion of surrounding genes could be an alternative
leukemogenic mechanism for translocations lack-
ing functionally signiﬁcant fusion transcripts (Cools
et al., 2002). With this in mind, we set out to study
the expression of genes located around the break-
point in this patient. Analysis of the April 2001
assembly of the human genome at the UCSC Ge-
nome Browser (http://genome.ucsc.edu/) led us to
measure the expression of four genes in the bone
marrow of the patient and in the bone marrow of
three normal subjects. Comparison by semiquanti-
tative RT-PCR revealed that RPL11, a gene im-
mediately centromeric to MDS2 (63.5 kb), shows
higher expression levels in the sample of the pa-
tient with the t(1;12) than those in normal bone
marrow samples. RPL11 encodes a ribosomal pro-
tein that is a component of the 60S subunit and
belongs to the L5P family of ribosomal proteins. As
is typical for genes encoding ribosomal proteins,
there are multiple processed pseudogenes of this
gene dispersed through the genome. Although the
role that RPL11 overexpression may play in the
development of MDS is not clear at present, our
ﬁndings support the notion that at least part of the
pathogenic process initiated by the translocation
could be the result of position effects, placing sur-
rounding genes in a different chromatin context
and thereby modifying their expression levels.
MDS2 does not seem to be a gene frequently
involved in 1p36 rearrangements. FISH analysis of
a further 10 patients with hematological malignan-
cies and reciprocal translocations involving 1p36
showed that the breakpoints on this region are
distributed throughout this band, and we found no
breakpoints within the MDS2 locus in any of the
cases.
The other translocation found in the patient
clone probably is important for the malignant trans-
formation. Using FISH, we showed that this is a
complex translocation involving chromosomes 9,
11, and 21. We localized the breakpoint in 9q34.13,
between the clones RP11 98H23 and RP11
247A12; although the distance between these two
BACs is less than 100 kb, there are several candi-
date genes in this region. The two breakpoints in
chromosome 11 are in 11q13.4. There are two can-
didate genes in this region, C11ORF23 and LRP5, a
low-density lipoprotein receptor-related protein 7.
In conclusion, a novel ETV6 partner gene,
MDS2, located in 1p36.1 is reported. Determining
the function of this gene will help to delineate the
pathogenic mechanisms triggered by this translo-
cation. Likewise, the changes in the expression of
surrounding genes that we have shown support the
notion that position effects could be partly respon-
sible for the development of MDS in this patient.
ACKNOWLEDGMENTS
We thank Dr. Peter Marynen and Dr. Jan Cools
(Center for Human Genetics, University of Leu-
ven) for helpful discussion; and Nekane Sanjose´,
Carmen Ferreira, and Ana Dı´az (Department of
Genetics, University of Navarra) and Elena Sa´ez de
Blas and Victoria Aranda (Laboratory of Pathology
and Gene Therapy, Department of Medicine, Uni-
versity of Navarra) for technical assistance.
REFERENCES
Beverloo HB, Panagopoulos I, Isaksson M, van Wering E, van
Drunen E, de Klein A, Johansson B, Slater R. 2001. Fusion of the
homeobox gene HLXB9 and the ETV6 gene in infant acute
myeloid leukemias with the t(7;12)(q36;p13). Cancer Res 61:
5374–5377.
Buijs A, Sherr S, van Baal S, van Bezouw S, van der Plas D, Geurts
van Kessel A, Riegman P, Lekanne Deprez R, Zwarthoff E,
Hagemeijer A. 1995. Translocation (12;22) (p13;q11) in myelopro-
liferative disorders results in fusion of the ETS-like TEL gene on
12p13 to the MN1 gene on 22q11. Oncogene 10:1511–1519.
Cazzaniga G, Tosi S, Aloisi A, Giudici G, Daniotti M, Pioltelli P,
Kearney L, Biondi A. 1999. The tyrosine kinase abl-related gene
ARG is fused to ETV6 in an AML-M4Eo patient with a t(1;
12)(q25;p13): molecular cloning of both reciprocal transcripts.
Blood 94:4370–4373.
Cazzaniga G, Daniotti M, Tosi S, Giudici G, Aloisi A, Pogliani E,
Kearney L, Biondi A. 2001. The paired box domain gene PAX5 is
fused to ETV6/TEL in an acute lymphoblastic leukemia case.
Cancer Res 61:4666–4670.
Chase A, Reiter A, Burci L, Cazzaniga G, Biondi A, Pickard J,
Roberts IA, Goldman JM, Cross NC. 1999. Fusion of ETV6 to the
caudal-related homeobox gene CDX2 in acute myeloid leukemia
with the t(12;13)(p13;q12). Blood 93:1025–1031.
Cools J, Peeters P, Voet T, Aventin A, Mecucci C, Grandchamp B,
Marynen P. 1999. Genomic organization of human JAK2 and
mutation analysis of its JH2-domain in leukemia. Cytogenet Cell
Genet 85:260–266.
Cools J, Mentens N, Odero MD, Peeters P, Wlodarska I,. Delforge
M, Hagemeijer A, Marynen P. 2002. Evidence for position effects
as a variant ETV6-mediated leukemogenic mechanism in my-
eloid leukemias with a t(4;12)(q11–q12;p13) or t(5;12)(q31;p13).
Blood 99:1776–1784.
18 ODERO ET AL.
Eguchi M, Eguchi-Ishimae M, Tojo A, Morishita K, Suzuki K, Sato
Y, Kudoh S, Tanaka K, Setoyama M, Nagamura F, Asano S,
Kamada N. 1999. Fusion of ETV6 to neurotrophin-3 receptor
TRKC in acute myeloid leukemia with t(12;15)(p13;q25). Blood
93:1355–1363.
Fenrick R, Wang L, Nip J, Amann JM, Rooney RJ, Walker-Daniels
J, Crawford HC, Hulboy DL, Kinch MS, Matrisian LM, Hiebert
SW. 2000. TEL, a putative tumor suppressor, modulates cell
growth and cell morphology of ras-transformed cells while re-
pressing the transcription of stromelysin-1. Mol Cell Biol 20:
5828–5839.
Golub TR, Barker GF, Lovett M, Gilliland DG. 1994. Fusion of
PDGF receptor beta to a novel ets-like gene, tel, in chronic
myelomonocytic leukemia with t(5;12) chromosomal transloca-
tion. Cell 77:307–316.
Golub TR, Barker GF, Bohlander SK, Hiebert SW, Ward DC,
Bray-Ward P, Morgan E, Raimondi SC, Rowley JD, Gilliland DG.
1995. Fusion of the TEL gene on 12p13 to the AML1 gene on
21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci USA
92:4917–4921.
Iijima Y, Ito T, Oikawa T, Eguchi M, Eguchi-Ishimae M, Kamada
N, Kishi K, Asano S, Sakaki Y, Sato Y. 2000. A new ETV6/TEL
partner gene, ARG (ABL-related gene or ABL2), identiﬁed in an
AML-M3 cell line with a t(1;12)(q25;p13) translocation. Blood
95:2126–2131.
Kuno Y, Abe A, Emi N, Iida M, Yokozawa T, Towatari M, Tanimoto
M, Saito H. 2001. Constitutive kinase activation of the TEL-Syk
fusion gene in myelodysplastic syndrome with t(9;12)(q22;p12).
Blood 97:1050–1055.
Lopez RG, Carron C, Oury C, Gardellin P, Bernard O, Ghysdael J.
1999. TEL is a sequence-speciﬁc transcriptional repressor. J Biol
Chem 274:30132–30138.
Odero MD, Carlson K, Calasanz MJ, Lahortiga I, Chinwalla V,
Rowley JD. 2001. Identiﬁcation of new translocations involving
ETV6 in hematologic malignancies by ﬂuorescence in situ hy-
bridization and spectral karyotyping. Genes Chromosomes Cancer
31:134–142.
Papadopoulos P, Ridge SA, Boucher CA, Stocking C, Wiedemann
LM. 1995. The novel activation of ABL by fusion to an ets-related
gene, TEL. Cancer Res 55:34–38.
Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, Philip
P, Monpoux F, Van Rompaey L, Baens M, Van den Berghe H,
Marynen P. 1997a. Fusion of TEL, the ETS-variant gene 6
(ETV6), to the receptor-associated kinase JAK2 as a result of
t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood
90:2535–2540.
Peeters P, Wlodarska I, Baens M, Criel A, Selleslag D, Hagemeijer
A, Van den Berghe H, Marynen P. 1997b. Fusion of ETV6 to
MDS1/EVI1 as a result of t(3;12)(q26;p13) in myeloproliferative
disorders. Cancer Res 57:564–569.
Romana SP, Le Coniat M, Berger R. 1994. t(12;21): a new recurrent
translocation in acute lymphoblastic leukemia. Genes Chromo-
somes Cancer 9:186–191.
Salomon-Nguyen F, Della-Valle V, Mauchauffe M, Busson-Le Co-
niat M, Ghysdael J, Berger R, Bernard OA. 2000. The t(1;12)(q21;
p13) translocation of human acute myeloblastic leukemia results
in a TEL-ARNT fusion. Proc Natl Acad Sci USA 97:6757–6762.
Sato Y, Bohlander SK, Kobayashi H, Reshmi S, Suto Y, Davis EM,
Espinosa R, Hoopes R, Montgomery KT, Kucherlapati RS, Le
Beau MM, Rowley JD. 1997. Heterogeneity in the breakpoints in
balanced rearrangements involving band 12p13 in hematologic
malignancies identiﬁed by ﬂuorescence in situ hybridization:
TEL (ETV6) is involved in only one half. Blood 90:4886–4893.
Suto Y, Sato Y, Smith SD, Rowley JD, Bohlander SK. 1997. A
t(6;12)(q23;p13) results in the fusion of ETV6 to a novel gene,
STL, in a B-cell ALL cell line. Genes Chromosomes Cancer
18:254–268.
Wang LC, Swat W, Fujiwara Y, Davidson L, Visvader J, Kuo F, Alt
FW, Gilliland DG, Golub TR, Orkin SH. 1998. The TEL/ETV6
gene is required speciﬁcally for hematopoiesis in the bone mar-
row. Genes Dev 12:2392–2402.
Yagasaki F, Jinnai I, Yoshida S, Yokoyama Y, Matsuda A, Kusumoto
S, Kobayashi H, Terasaki H, Ohyashiki K, Asou N, Murohashi I,
Bessho M, Hirashima K. 1999. Fusion of TEL/ETV6 to a novel
ACS2 in myelodysplastic syndrome and acute myelogenous leu-
kemia with t(5;12)(q31;p13). Genes Chromosomes Cancer 26:
192–202.
19MDS2 ON 1p36.1 IS A NOVEL ETV6 PARTNER IN MDS
